Chrome Extension
WeChat Mini Program
Use on ChatGLM

US Physician Perspective on the Use of Biomarker and Ctdna Testing in Patients with Melanoma.

Rachel A. Fischer, Isabel Ryan, Kristine De La Torre, Cody Barnett, Viren S. Sehgal, Joan B. Levy,Jason J. Luke,Andrew S. Poklepovic,Marc S. Hurlbert

CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY(2024)

Cited 0|Views15
No score
Abstract
New treatments have increased survival of patients with melanoma, and methods to monitor patients throughout the disease process are needed. Circulating tumor DNA (ctDNA) is a predictive and prognostic biomarker that may allow routine, real-time monitoring of disease status. We surveyed 44 US physicians to understand their preferences and practice patterns for biomarker and ctDNA testing in their patients with melanoma. Tumor biomarker testing was often ordered in stage IIIA-IV patients. Barriers to biomarker testing include insufficient tissue (60%) and lack of insurance coverage (54%). ctDNA testing was ordered by 16 -18% of physicians for stages II -IV. Reasons for not using ctDNA testing included lack of prospective data (41%), ctDNA testing used for research only (18%), and others. Physicians ( >= 74%) believed that ctDNA assays could help with monitoring and treatment selection throughout the disease process. Physicians consider ctDNA testing potentially valuable for clinical decision -making but cited concerns that should be addressed.
More
Translated text
Key words
Melanoma,CtDNA,Biomarker,Monitoring,Treatment selection,US physicians,Survey
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined